Want to see HK:6118 full AI Analyst Report?
Total Valuation
Austar Lifesciences Ltd. has a market cap or net worth of HK$351.12M. The enterprise value is HK$485.11M.
Market CapHK$351.12M
Enterprise ValueHK$485.11M
Share Statistics
Austar Lifesciences Ltd. has 512,582,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding512,582,030
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Austar Lifesciences Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.06%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.06%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee1.04M
Profits Per Employee22.43K
Employee Count1,468
Asset Turnover0.72
Inventory Turnover4.42
Valuation Ratios
The current PE Ratio of Austar Lifesciences Ltd. is 17.4. Austar Lifesciences Ltd.’s PEG ratio is 0.11.
PE Ratio17.4
PS Ratio0.26
PB Ratio0.49
Price to FCF4.02
Price to Operating Cash Flow1.61
PEG Ratio0.11
Income Statement
In the last 12 months, Austar Lifesciences Ltd. had revenue of 1.53B and earned 33.80M in profits. Earnings per share was 0.07.
Revenue1.53B
Gross Profit293.27M
Operating Income54.15M
Pretax Income48.13M
Net Income33.80M
EBITDA92.28M
Earnings Per Share (EPS)0.07
Cash Flow
In the last 12 months, operating cash flow was 186.17M and capital expenditures -33.75M, giving a free cash flow of 152.42M billion.
Operating Cash Flow186.17M
Free Cash Flow152.42M
Free Cash Flow per Share0.30
Dividends & Yields
Austar Lifesciences Ltd. pays an annual dividend of HK$0.05, resulting in a dividend yield of 1.52%
Dividend Per ShareHK$0.05
Dividend Yield1.52%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change-49.26%
50-Day Moving Average0.71
200-Day Moving Average0.77
Relative Strength Index (RSI)41.83
Average Volume (3m)26.07K
Important Dates
Austar Lifesciences Ltd. upcoming earnings date is Mar 30, 2027, TBA (Confirmed).
Last Earnings DateAug 25, 2026
Next Earnings DateMar 30, 2027
Ex-Dividend Date―
Financial Position
Austar Lifesciences Ltd. as a current ratio of 1.36, with Debt / Equity ratio of 43.63%
Current Ratio1.36
Quick Ratio1.12
Debt to Market Cap0.80
Net Debt to EBITDA0.73
Interest Coverage Ratio4.59
Taxes
In the past 12 months, Austar Lifesciences Ltd. has paid 15.25M in taxes.
Income Tax15.25M
Effective Tax Rate0.32
Enterprise Valuation
Austar Lifesciences Ltd. EV to EBITDA ratio is 5.07, with an EV/FCF ratio of 4.69.
EV to Sales0.31
EV to EBITDA5.07
EV to Free Cash Flow4.69
EV to Operating Cash Flow3.65
Balance Sheet
Austar Lifesciences Ltd. has HK$255.32M in cash and marketable securities with HK$362.65M in debt, giving a net cash position of -HK$107.33M billion.
Cash & Marketable SecuritiesHK$255.32M
Total DebtHK$362.65M
Net Cash-HK$107.33M
Net Cash Per Share-HK$0.21
Tangible Book Value Per ShareHK$1.53
Margins
Gross margin is 18.11%, with operating margin of 3.54%, and net profit margin of 2.21%.
Gross Margin18.11%
Operating Margin3.54%
Pretax Margin3.14%
Net Profit Margin2.21%
EBITDA Margin6.03%
EBIT Margin2.82%
Analyst Forecast
The average price target for Austar Lifesciences Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast14.04%
EPS Growth Forecast-49.19%